Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab–irinotecan in children with low‐grade glioma?

The association of bevacizumab and irinotecan has been shown to display a quick efficacy in low‐grade glioma (LGG), but most patients relapse within months after cessation of therapy. From October 2012 to March 2014, four patients have been treated with irinotecan–bevacizumab followed by a metronomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Heng, Marie Amélie, Padovani, Laetitia, Dory‐Lautrec, Philippe, Gentet, Jean Claude, Verschuur, Arnaud, Pasquier, Eddy, Figarella‐Branger, Dominique, Scavarda, Didier, André, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944881/
https://www.ncbi.nlm.nih.gov/pubmed/27037940
http://dx.doi.org/10.1002/cam4.699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944881/
https://www.ncbi.nlm.nih.gov/pubmed/27037940
http://dx.doi.org/10.1002/cam4.699

Ejemplares similares